Halozyme Therapeutics, Inc. (HALO): who owns it and who trades it
As of Nov 16, 2026, HALO insiders reported 106 open-market sales worth $49.8M and no purchases in the last 12 months, with 96% of the sale value made under pre-set 10b5-1 plans. The largest seller was Helen Torley (CEO), with $44M. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Halozyme Therapeutics
From the latest filingsOverall: more selling than buying. Insiders and Congress mostly sold. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns HALO
666 funds and institutions reported HALO shares worth $9.8B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 11.2%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 13.27M | 11.19% | $1B | No change |
| Vanguard Capital Management LLC | 5.35M | 4.51% | $419M | +2% |
| Vanguard Portfolio Management LLC | 5.30M | 4.47% | $415M | +1% |
| State Street Corp | 5.18M | 4.37% | $405M | +5% |
| Invesco Ltd. | 3.18M | 2.68% | $249M | -21% |
| Morgan Stanley | 2.83M | 2.39% | $222M | +11% |
| Boston Partners | 2.77M | 2.34% | $217M | +3% |
| Bank of America Corp | 2.74M | 2.31% | $215M | -6% |
| Geode Capital Management, LLC | 2.52M | 2.12% | $197M | +1% |
| William Blair Investment Management, LLC | 2.51M | 2.12% | $197M | -1% |
| Snyder Capital Management L P | 2.40M | 2.02% | $188M | +3% |
| Dimensional Fund Advisors LP | 2.09M | 1.76% | $164M | +0% |
| D. E. Shaw & Co., Inc. | 2.01M | 1.69% | $157M | +7% |
| Assenagon Asset Management S.A. | 2.00M | 1.68% | $156M | – |
| Los Angeles Capital Management LLC | 1.94M | 1.63% | $152M | +181% |
| Royal London Asset Management Ltd | 1.81M | 1.53% | $142M | +12% |
| Arrowstreet Capital, Limited Partnership | 1.70M | 1.44% | $133M | -11% |
| Alliancebernstein L.P. | 1.70M | 1.43% | $110M | -2% |
| Two Sigma Investments, LP | 1.65M | 1.39% | $129M | +4% |
| UBS Group AG | 1.49M | 1.26% | $117M | +63% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, HALO insiders reported $0 of open-market purchases and $49.8M of sales. 96% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 16, 2026 | Helen Torley | CEO | Sale plan | 7,283 | $96.85 | $705K | Form 4 |
| Nov 16, 2026 | Helen Torley | CEO | Sale plan | 4,802 | $97.95 | $470K | Form 4 |
| Nov 16, 2026 | Helen Torley | CEO | Sale plan | 1,586 | $98.89 | $157K | Form 4 |
| Nov 16, 2026 | Helen Torley | CEO | Sale plan | 4,897 | $100.10 | $490K | Form 4 |
| Nov 16, 2026 | Helen Torley | CEO | Sale plan | 1,244 | $101.06 | $126K | Form 4 |
| Nov 16, 2026 | Helen Torley | CEO | Sale plan | 188 | $101.72 | $19.1K | Form 4 |
| Nov 13, 2026 | Helen Torley | CEO | Sale plan | 7,992 | $100.02 | $799K | Form 4 |
| Nov 13, 2026 | Helen Torley | CEO | Sale plan | 12,008 | $100.61 | $1.2M | Form 4 |
| Nov 12, 2026 | Helen Torley | CEO | Sale plan | 10,711 | $101.09 | $1.1M | Form 4 |
| Nov 12, 2026 | Helen Torley | CEO | Sale plan | 9,289 | $101.49 | $943K | Form 4 |
| Oct 8, 2026 | Helen Torley | CEO | Sale plan | 4,810 | $108.18 | $520K | Form 4 |
| Oct 8, 2026 | Helen Torley | CEO | Sale plan | 3,090 | $108.91 | $337K | Form 4 |
| Oct 8, 2026 | Helen Torley | CEO | Sale plan | 11,900 | $110.00 | $1.3M | Form 4 |
| Oct 8, 2026 | Helen Torley | CEO | Sale plan | 200 | $110.51 | $22.1K | Form 4 |
| Oct 7, 2026 | Helen Torley | CEO | Sale plan | 8,600 | $111.03 | $955K | Form 4 |
| Oct 7, 2026 | Helen Torley | CEO | Sale plan | 10,300 | $111.84 | $1.2M | Form 4 |
| Oct 7, 2026 | Helen Torley | CEO | Sale plan | 900 | $112.78 | $102K | Form 4 |
| Oct 7, 2026 | Helen Torley | CEO | Sale plan | 200 | $113.69 | $22.7K | Form 4 |
| Oct 6, 2026 | Helen Torley | CEO | Sale plan | 2,300 | $107.90 | $248K | Form 4 |
| Oct 6, 2026 | Helen Torley | CEO | Sale plan | 6,000 | $109.33 | $656K | Form 4 |
| Oct 6, 2026 | Helen Torley | CEO | Sale plan | 9,920 | $109.89 | $1.1M | Form 4 |
| Oct 6, 2026 | Helen Torley | CEO | Sale plan | 1,780 | $110.81 | $197K | Form 4 |
| Oct 1, 2026 | Matthew L. Posard | Director | Sale plan | 730 | $107.17 | $78.2K | Form 4 |
| Oct 1, 2026 | Matthew L. Posard | Director | Sale plan | 3,300 | $108.45 | $358K | Form 4 |
| Oct 1, 2026 | Matthew L. Posard | Director | Sale plan | 1,100 | $109.57 | $121K | Form 4 |
| Oct 1, 2026 | Matthew L. Posard | Director | Sale plan | 100 | $110.04 | $11K | Form 4 |
| Sep 16, 2026 | Matthew L. Posard | Director | Sale plan | 3,000 | $106.83 | $320K | Form 4 |
| Sep 16, 2026 | Matthew L. Posard | Director | Sale plan | 8,896 | $108.04 | $961K | Form 4 |
| Sep 16, 2026 | Matthew L. Posard | Director | Sale plan | 3,100 | $106.13 | $329K | Form 4 |
| Sep 16, 2026 | Matthew L. Posard | Director | Sale plan | 4,000 | $108.99 | $436K | Form 4 |
| Sep 11, 2026 | Helen Torley | CEO | Sale plan | 4,508 | $107.55 | $485K | Form 4 |
| Sep 11, 2026 | Helen Torley | CEO | Sale plan | 15,492 | $107.15 | $1.7M | Form 4 |
| Sep 10, 2026 | Helen Torley | CEO | Sale plan | 14,588 | $107.01 | $1.6M | Form 4 |
| Sep 10, 2026 | Helen Torley | CEO | Sale plan | 5,412 | $107.58 | $582K | Form 4 |
| Sep 9, 2026 | Helen Torley | CEO | Sale plan | 100 | $108.67 | $10.9K | Form 4 |
| Sep 9, 2026 | Helen Torley | CEO | Sale plan | 6,596 | $107.82 | $711K | Form 4 |
| Sep 9, 2026 | Helen Torley | CEO | Sale plan | 13,304 | $107.22 | $1.4M | Form 4 |
| Aug 19, 2026 | Helen Torley | CEO | Sale plan | 7,200 | $106.36 | $766K | Form 4 |
| Aug 19, 2026 | Helen Torley | CEO | Sale plan | 9,600 | $107.22 | $1M | Form 4 |
| Aug 19, 2026 | Helen Torley | CEO | Sale plan | 3,200 | $107.77 | $345K | Form 4 |
| Aug 18, 2026 | Helen Torley | CEO | Sale plan | 5,703 | $103.08 | $588K | Form 4 |
| Aug 18, 2026 | Helen Torley | CEO | Sale plan | 4,897 | $104.11 | $510K | Form 4 |
| Aug 18, 2026 | Helen Torley | CEO | Sale plan | 9,400 | $104.87 | $986K | Form 4 |
| Aug 17, 2026 | Helen Torley | CEO | Sale plan | 7,500 | $103.48 | $776K | Form 4 |
| Aug 17, 2026 | Helen Torley | CEO | Sale plan | 9,000 | $102.55 | $923K | Form 4 |
| Aug 17, 2026 | Helen Torley | CEO | Sale plan | 2,100 | $101.77 | $214K | Form 4 |
| Aug 17, 2026 | Helen Torley | CEO | Sale plan | 500 | $100.46 | $50.2K | Form 4 |
| Aug 17, 2026 | Helen Torley | CEO | Sale plan | 900 | $98.96 | $89.1K | Form 4 |
| Aug 10, 2026 | Bernadette Connaughton | Director | Sale plan | 1,626 | $102.80 | $167K | Form 4 |
| Jul 8, 2026 | Helen Torley | CEO | Sale plan | 888 | $79.28 | $70.4K | Form 4 |
| Jul 8, 2026 | Helen Torley | CEO | Sale plan | 1,035 | $80.19 | $83K | Form 4 |
| Jul 1, 2026 | Bernadette Connaughton | Director | Sale plan | 625 | $77.21 | $48.3K | Form 4 |
| Jul 1, 2026 | Bernadette Connaughton | Director | Sale plan | 1,000 | $76.40 | $76.4K | Form 4 |
| Jun 29, 2026 | Mahesh Krishnan | Director | Sale plan | 7,304 | $75.00 | $548K | Form 4 |
| Jun 3, 2026 | Helen Torley | CEO | Sale plan | 6,100 | $69.69 | $425K | Form 4 |
| Jun 3, 2026 | Helen Torley | CEO | Sale plan | 400 | $66.37 | $26.5K | Form 4 |
| Jun 3, 2026 | Helen Torley | CEO | Sale plan | 1,500 | $67.68 | $102K | Form 4 |
| Jun 3, 2026 | Helen Torley | CEO | Sale plan | 2,000 | $68.74 | $137K | Form 4 |
| Jun 2, 2026 | Helen Torley | CEO | Sale plan | 3,400 | $66.75 | $227K | Form 4 |
| Jun 2, 2026 | Helen Torley | CEO | Sale plan | 16,600 | $66.31 | $1.1M | Form 4 |
| Jun 1, 2026 | Helen Torley | CEO | Sale plan | 1,610 | $66.39 | $107K | Form 4 |
| Jun 1, 2026 | Helen Torley | CEO | Sale plan | 12,989 | $67.41 | $876K | Form 4 |
| Jun 1, 2026 | Helen Torley | CEO | Sale plan | 5,401 | $68.35 | $369K | Form 4 |
| Jun 1, 2026 | Bernadette Connaughton | Director | Sale plan | 1,625 | $66.21 | $108K | Form 4 |
| May 13, 2026 | Helen Torley | CEO | Sale plan | 2,100 | $68.10 | $143K | Form 4 |
| May 13, 2026 | Helen Torley | CEO | Sale plan | 3,350 | $68.88 | $231K | Form 4 |
| May 13, 2026 | Helen Torley | CEO | Sale plan | 3,950 | $69.79 | $276K | Form 4 |
| May 13, 2026 | Helen Torley | CEO | Sale plan | 600 | $70.81 | $42.5K | Form 4 |
| May 12, 2026 | Helen Torley | CEO | Sale plan | 2,800 | $73.12 | $205K | Form 4 |
| May 12, 2026 | Helen Torley | CEO | Sale plan | 100 | $67.85 | $6.8K | Form 4 |
| May 12, 2026 | Helen Torley | CEO | Sale plan | 1,398 | $70.29 | $98.3K | Form 4 |
| May 12, 2026 | Helen Torley | CEO | Sale plan | 9,802 | $71.37 | $700K | Form 4 |
| May 12, 2026 | Helen Torley | CEO | Sale plan | 5,900 | $72.15 | $426K | Form 4 |
| May 11, 2026 | Helen Torley | CEO | Sale plan | 9,725 | $64.63 | $629K | Form 4 |
| May 11, 2026 | Helen Torley | CEO | Sale plan | 3,575 | $65.46 | $234K | Form 4 |
| May 11, 2026 | Helen Torley | CEO | Sale plan | 6,700 | $66.33 | $444K | Form 4 |
| May 1, 2026 | Bernadette Connaughton | Director | Sale plan | 1,625 | $63.48 | $103K | Form 4 |
| Apr 6, 2026 | Helen Torley | CEO | Sale plan | 5,900 | $63.14 | $373K | Form 4 |
| Apr 6, 2026 | Helen Torley | CEO | Sale plan | 4,100 | $64.02 | $262K | Form 4 |
| Apr 2, 2026 | Helen Torley | CEO | Sale plan | 4,200 | $64.89 | $273K | Form 4 |
| Apr 2, 2026 | Helen Torley | CEO | Sale plan | 15,800 | $64.06 | $1M | Form 4 |
| Apr 1, 2026 | Helen Torley | CEO | Sale plan | 19,000 | $65.36 | $1.2M | Form 4 |
| Apr 1, 2026 | Helen Torley | CEO | Sale plan | 1,000 | $65.71 | $65.7K | Form 4 |
| Mar 10, 2026 | Cortney Caudill | Vice president | Sale | 8,857 | $67.64 | $599K | Form 4 |
| Mar 9, 2026 | Cortney Caudill | Vice president | Sale | 2,100 | $68.25 | $143K | Form 4 |
| Mar 9, 2026 | Cortney Caudill | Vice president | Sale | 17,900 | $67.75 | $1.2M | Form 4 |
| Mar 4, 2026 | Helen Torley | CEO | Sale plan | 7,329 | $69.94 | $513K | Form 4 |
| Mar 4, 2026 | Helen Torley | CEO | Sale plan | 2,671 | $70.95 | $190K | Form 4 |
| Mar 3, 2026 | Helen Torley | CEO | Sale plan | 13,481 | $68.85 | $928K | Form 4 |
| Mar 3, 2026 | Helen Torley | CEO | Sale plan | 6,519 | $69.33 | $452K | Form 4 |
| Mar 2, 2026 | Helen Torley | CEO | Sale plan | 4,100 | $69.20 | $284K | Form 4 |
| Mar 2, 2026 | Helen Torley | CEO | Sale plan | 15,322 | $69.80 | $1.1M | Form 4 |
| Mar 2, 2026 | Helen Torley | CEO | Sale plan | 578 | $70.46 | $40.7K | Form 4 |
| Feb 5, 2026 | Helen Torley | CEO | Sale plan | 5,376 | $78.38 | $421K | Form 4 |
| Feb 5, 2026 | Helen Torley | CEO | Sale plan | 4,624 | $78.94 | $365K | Form 4 |
| Feb 4, 2026 | Helen Torley | CEO | Sale plan | 10,100 | $77.54 | $783K | Form 4 |
| Feb 4, 2026 | Helen Torley | CEO | Sale plan | 9,900 | $76.94 | $762K | Form 4 |
| Feb 3, 2026 | Helen Torley | CEO | Sale plan | 2,551 | $74.88 | $191K | Form 4 |
| Feb 3, 2026 | Helen Torley | CEO | Sale plan | 9,659 | $75.94 | $734K | Form 4 |
| Feb 3, 2026 | Helen Torley | CEO | Sale plan | 7,790 | $76.73 | $598K | Form 4 |
Latest 100 of 106 trades in the last 12 months.
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Helen Torley | PRESIDENT AND CEO, Director | – | $44M | Nov 16, 2026 |
| Matthew L. Posard | Director | – | $2.6M | Oct 1, 2026 |
| Cortney Caudill | SVP, CHIEF OPERATING OFFICER | – | $2M | Mar 10, 2026 |
| Bernadette Connaughton | Director | – | $702K | Aug 10, 2026 |
| Mahesh Krishnan | Director | – | $548K | Jun 29, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
HALO short interest
High short interest. 12.0% of HALO shares are sold short: about 1 share in 8. Over the last 12 reports the number of shares short went up 2%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 13.65M HALO shares were sold short, 12.0% of the shares outstanding, unchanged from the report before. At the average daily volume of 2.01M shares, buying them all back would take about 6.8 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 13.65M | 12.03% | No change | 2.01M | 6.8 |
| Oct 15, 2026 | 13.65M | 12.03% | -11% | 2.22M | 6.2 |
| Sep 30, 2026 | 15.30M | 13.48% | +1% | 3.37M | 4.5 |
| Sep 15, 2026 | 15.15M | 13.35% | +2% | 1.31M | 11.6 |
| Aug 31, 2026 | 14.88M | 13.11% | +2% | 1.71M | 8.7 |
| Aug 14, 2026 | 14.64M | 12.90% | +4% | 2.92M | 5.0 |
| Jul 31, 2026 | 14.02M | 12.35% | +5% | 1.68M | 8.3 |
| Jul 15, 2026 | 13.30M | 11.21% | +1% | 1.83M | 7.3 |
| Jun 30, 2026 | 13.23M | 11.15% | +2% | 2.11M | 6.3 |
| Jun 15, 2026 | 12.95M | 10.92% | -5% | 1.65M | 7.8 |
| May 29, 2026 | 13.64M | 11.50% | +2% | 1.68M | 8.1 |
| May 15, 2026 | 13.39M | 11.29% | -7% | 1.99M | 6.7 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Members of Congress who traded HALO
Since Nov 17, 2024, 1 member of Congress reported 1 purchase and 2 sales of HALO. The latest was a sale by Gilbert Ray Cisneros, Jr. on Sep 29, 2026, reported Oct 12, 2026.
Purchases 1Sales 2
Reported trades
| Trade date | Member | Type | Amount | Owner | Reported | Source |
|---|---|---|---|---|---|---|
| Sep 29, 2026 | Gilbert Ray Cisneros, Jr. (D-CA) | Partial sale | $1K–$15K | Self | Oct 12, 2026 | Report |
| Mar 9, 2026 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Apr 7, 2026 | Report |
| Mar 24, 2025 | Gilbert Ray Cisneros, Jr. (D-CA) | Partial sale | $1K–$15K | Self | Apr 7, 2025 | Report |
Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work
Halozyme Therapeutics company events
Halozyme Therapeutics filed 18 reports on Form 8-K in the last 12 months, 8 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Sep 30, 2026LeadershipJames Daly was elected to the Board of Directors of Halozyme Therapeutics, Inc. Filing
- Sep 22, 2026AgreementHalozyme Therapeutics, Inc. completed its previously announced sale of $1,500.0 million of 1.50% Convertible Senior Notes due 2033, including $200.0 million in of its Convertible Notes purchased pursuant to the exercise by the initial purchasers of the Convertible Notes of the option to purchase… Filing
- Sep 18, 2026AnnouncementHalozyme Therapeutics, Inc. issued a press release announcing the pricing of its offering of $1.3 billion of convertible senior notes due 2033. Filing
- Sep 16, 2026AnnouncementHalozyme Therapeutics, Inc. issued a press release announcing that it proposes to offer, subject to market conditions and other factors, $1.05 billion of convertible senior notes due 2033. Filing
- Aug 18, 2026LeadershipDannielle Appelhans was elected to the Board of Directors of Halozyme Therapeutics, Inc. Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- Jul 2, 2026LeadershipHalozyme Therapeutics, Inc. announced an update to its senior management structure. Filing
- May 11, 2026ResultsReleased financial results. Filing
- May 7, 2026VoteReported shareholder vote results. Filing
- Apr 30, 2026LeadershipHalozyme Therapeutics, Inc. announced that Darren Snellgrove has been appointed to serve as the Company’s Chief Financial Officer, effective June 8, 2026. Filing
- Apr 24, 2026RulesChanged its bylaws or articles. Filing
- Mar 12, 2026LeadershipHalozyme Therapeutics, Inc. announced that David Ramsay has been appointed to serve as the Company’s Interim Chief Financial Officer, effective March 23, 2026. Filing
- Feb 17, 2026ResultsReleased financial results. Filing
- Jan 28, 2026ResultsReleased financial results. Filing
- Dec 9, 2025LeadershipThe Compensation Committee of the Board of Directors of Halozyme Therapeutics, Inc. approved a performance-based restricted stock unit grant for Dr. Helen Torley, Chief Executive Officer of the Company. Filing
- Dec 8, 2025LeadershipJames Lang was elected to the Board of Directors of Halozyme Therapeutics, Inc. Filing
- Nov 24, 2025LeadershipAs previously disclosed, Halozyme Therapeutics, Inc. announced a transition plan in which Nicole LaBrosse, Senior Vice President, Chief Financial Officer will continue to serve as the Company’s Chief Financial Officer until the earliest of when a new chief financial officer is hired, March 30, 2026… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Halozyme Therapeutics financials
Famous investors that hold HALO
5 of the 50 well-known investors we track reported holding HALO in their latest 13F filing. The largest position is Ken Griffin's, worth $66.1M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 598,639 | $66.1M | 0.0% | +107% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 598,111 | $66M | 0.1% | +25% |
| Ray Dalio · Bridgewater Associates | Q3 2026 | 328,269 | $36.2M | 0.2% | -29% |
| Israel Englander · Millennium Management | Q3 2026 | 198,321 | $21.9M | 0.0% | +899% |
| George Soros · Soros Fund Management | Q3 2026 | 64,118 | $7.1M | 0.1% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Halozyme Therapeutics, Inc. (HALO) stock
Who owns the most HALO stock?
The largest reported owner of Halozyme Therapeutics, Inc. (HALO) is BlackRock, Inc., with 11.2% of the company. In total, 666 funds and institutions reported holding HALO at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are HALO insiders buying or selling?
In the last 12 months, HALO insiders reported no open-market purchases and 106 sales worth $49.8M. The latest trade was on Nov 16, 2026. See every trade.
What is the short interest in HALO?
As of Oct 30, 2026, 13.65M HALO shares were sold short, 12.0% of the shares outstanding, unchanged from the report before. At the average daily volume of 2.01M shares, buying them all back would take about 6.8 trading days (days to cover). See the history.
Have members of Congress traded HALO?
Yes. 1 member of Congress reported 1 purchase and 2 sales of HALO since Nov 17, 2024. The latest was reported on Oct 12, 2026. See the trades.
Which famous investors hold HALO?
5 of the 50 well-known investors we track reported HALO in their latest 13F filing, including Ken Griffin, Jim Simons, Ray Dalio. The largest position is worth $66.1M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.